Ankylosing spondylitis
Conference Coverage
TNF inhibitor may protect against axSpA sacroiliac joint progression
AMSTERDAM – In patients with axial spondyloarthritis, TNF inhibitor therapy is associated with slowing of sacroiliac joint radiographic...
Conference Coverage
Ankylosing spondylitis diagnosis linked to self-harm attempts
AMSTERDAM – Although a rare event, there is an increased risk of deliberate self-harm among those newly-diagnosed ankylosing spondylitis.
Conference Coverage
Axial SpA diagnostic strategies need not be sex-specific
AMSTERDAM – Imaging and HLA-B27 tests are key elements to identify early axial spondyloarthritis in both men and women.
Conference Coverage
EULAR scientific program highlights spectrum of translational research
Conference Coverage
Eye-opening findings cast spondyloarthritis in new light, expert says
New findings show that, in a surprisingly high number of patients, inflammatory back pain does not lead to axial SpA
Conference Coverage
Comorbid spondyloarthritis and fibromyalgia lower response to TNF inhibitors
LIVERPOOL, ENGLAND – Individuals with both axial spondyloarthritis and fibromyalgia respond to biologic therapy, but at a lower rate.
Conference Coverage
Physical therapy, exercise still relevant for ankylosing spondylitis
CAMBRIDGE, MASS.
Feature
Certolizumab pegol shows promise for nr-axSpA treatment
C-AXSPAND is the first year-long trial to show positive results vs. placebo in nonradiographic axial spondyloarthritis.
From the Journals
MACE risk similar across arthritis subtypes
The older age of patients with rheumatoid arthritis explained most of their elevated risk of major adverse cardiovascular events.
From the Journals
Reassurance for women taking certolizumab during pregnancy
Exposure to certolizumab pegol does not appear to be associated with an increased risk of fetal death or congenital malformations.
News from the FDA/CDC
TB in 2017: Good news and bad news
Incidence is lower than ever, but elimination is still a long way off.